Largest-ever clinical study of ketamine therapy shows that at-home model can be a safe, effective treatment for anxiety and depression; 62% fewer patients report suicidal ideation after four sessions

At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial

AUSTIN, Texas, July 18, 2022 /PRNewswire/ -- Mindbloom, the leading provider of at-home ketamine therapy, announced Monday the findings of the largest-ever peer-reviewed clinical study of ketamine therapy.

Authored by psychiatrists and researchers from MAPS, the Cleveland Clinic, UCSF, NYU and Houston Methodist, the study, which has been accepted into the Journal of Affective Disorders to be published in its October edition, shows that at-home sublingual ketamine therapy can be a safe, effective treatment for anxiety and depression.

Across a cohort of 1,247 patients, 89% of participants presenting with anxiety and/or depression showed an improvement in their symptoms after just four sessions.

In total, 63% of participants saw a greater than 50% improvement in their symptoms. These results are 34% stronger¹ than what has been observed in studies of traditional antidepressants (such as SSRIs) and 54% stronger than results shown in studies of psychotherapy.²

Outcomes were also shown to be 17% stronger than those observed in studies of ketamine infusion treatments, despite Mindbloom's sublingual ketamine treatments being cheaper and less invasive.

"This landmark study showed outcomes for at-home ketamine therapy that far exceeded those of traditional depression treatments," said Mindbloom Medical Director Dr. Leonardo Vando. "This therapy compares very favorably against studies on traditional treatments like SSRI antidepressants and talk therapy. We believe that the support provided by our clinicians and guides and the comfort of our at-home, needle-free administration method contribute to the therapy's effectiveness."

The study also found that 62% of patients presenting with suicidal ideation prior to treatment no longer reported any suicidal ideation after four sessions.

Side effects were also shown to be rare. Fewer than 5% of patients reported any side effects, and of the 1,247 patients in the study, only four dropped out of treatment due to adverse events.

"The results of this study make it clear that ketamine therapy is the future of mental healthcare," said Mindbloom Founder & CEO Dylan Beynon. "This groundbreaking study is an opportunity to dispel common misconceptions about ketamine therapy, and to help us bring its healing power to more people than ever before."

Mindbloom is the leader in ketamine therapy, offering a combination of science-backed medicine with clinician and guide support for people looking to improve their mental health and wellbeing. Founded by three-time entrepreneur Dylan Beynon, Mindbloom aims to address the mental health crisis through at-home ketamine therapy. This at-home approach increases access to an affordable, safe and effective emerging treatment option. For more information, visit www.mindbloom.com.

Press contact: Mikey Light [email protected] cc [email protected]

¹https://pubmed.ncbi.nlm.nih.gov/16390886/
² https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457213/

SOURCE Mindbloom